Loading
RV001V is a cancer vaccine from RhoVac APS, in registered phase 2 trials for prostate cancer.
RV001V is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by RhoVac APS, in prostate cancer. A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens.
1.RV001V slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RV001V" OR ABSTRACT:"RV001V") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RV001V, not a curated reading list.
Shares Prostate cancer and the tags pipeline, registry-only.
Shares Prostate cancer and the tags pipeline, registry-only.
Shares Prostate cancer and the tags pipeline, registry-only.
Shares Prostate cancer and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.